Advaxis, Inc. (NASDAQ:ADXS)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $0.55, but opened at $0.58. Advaxis shares last traded at $0.59, with a volume of 169,259 shares trading hands.
Separately, Zacks Investment Research lowered Advaxis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 30th.
The firm has a 50 day moving average of $0.37 and a 200-day moving average of $1.03. The company has a market cap of $9.93 million, a P/E ratio of -0.03 and a beta of 3.43.
Advaxis (NASDAQ:ADXS) last issued its quarterly earnings results on Monday, September 9th. The biotechnology company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.24. Advaxis had a negative return on equity of 67.08% and a negative net margin of 113.67%. The firm had revenue of $0.01 million during the quarter. Equities research analysts expect that Advaxis, Inc. will post -2.7 EPS for the current fiscal year.
Several large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in Advaxis by 53,633.7% during the second quarter. JPMorgan Chase & Co. now owns 51,047 shares of the biotechnology company’s stock worth $107,000 after buying an additional 50,952 shares in the last quarter. Renaissance Technologies LLC increased its position in Advaxis by 143.7% in the second quarter. Renaissance Technologies LLC now owns 501,000 shares of the biotechnology company’s stock worth $1,047,000 after purchasing an additional 295,444 shares during the period. Vanguard Group Inc. increased its position in Advaxis by 71.1% in the second quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock worth $481,000 after purchasing an additional 95,607 shares during the period. Finally, Sabby Management LLC raised its holdings in Advaxis by 3,547.9% during the 3rd quarter. Sabby Management LLC now owns 1,521,982 shares of the biotechnology company’s stock worth $403,000 after purchasing an additional 1,480,260 shares during the last quarter. Hedge funds and other institutional investors own 30.33% of the company’s stock.
Advaxis Company Profile (NASDAQ:ADXS)
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
Read More: Limitations to arbitrage trading
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.